Search for Clinical Trial Results

Sponsored By

Coxsackievirus Infections - 25 Studies Found

Status Study
Completed Study Name: A Safety Study of Two Intratumoural Doses of Coxsackievirus Type A21 in Melanoma Patients
Condition: Stage IV Melanoma
Date: 2007-02-19
Interventions: Drug: Coxsackievirus A21 Two doses of drug, separated by 48 hours
Recruiting Study Name: Study of Intratumoral CAVATAK™ (Coxsackievirus A21) and Ipilimumab in Patients With Advanced Melanoma
Condition: Melanoma
Date: 2014-11-26
Interventions:
  • Biological: CAVATAK CAVATAK is
Completed Study Name: Intratumoural Administration of Coxsackievirus A21 for the Control of Malignant Melanoma
Condition: Malignant Melanoma
Date: 2005-10-07
Interventions: Drug: Coxsackievirus A21
Completed Study Name: Coxsackie Virus A21 Administered Intravenously (IV) for Solid Tumour Cancers
Condition:
  • Melanoma
  • Breast Cancer
  • Prostate Cancer

Date: 2008-03-07
Interventions: Drug: CVA21 IV infusion, dose escalation of one or two infusions of escalating strength
Terminated Study Name: A Study of the Intratumoural Administration of CAVATAK to Head and Neck Cancer Patients
Condition: Head and Neck Cancer
Date: 2009-01-29
Interventions: Biological: Coxsackievirus A21 1, 3 or 6 doses of CAVATAK (10^9 TCID50) at 48 hour intervals.
Recruiting Study Name: Phase I Study of Intratumoral CAVATAK™ and Pembrolizumab in Subjects With Advanced Melanoma
Condition: Melanoma
Date: 2015-09-30
Interventions:
  • Biological: CAVATAK Maximum do
Completed Study Name: A Study of Intratumoral CAVATAK™ in Patients With Stage IIIc and Stage IV Malignant Melanoma
Condition: Malignant Melanoma
Date: 2010-10-20
Interventions: Biological: Coxsackievirus A21 (CVA21) CVA21 is a live oncolytic virus preparation derived from the non-
Completed Study Name: Efficacy and Safety of Intratumoral CAVATAK in Patients With Stage IIIc or IV Malignant Melanoma to Extend Dosing to 48 Weeks
Condition: Melanoma
Date: 2012-07-05
Interventions: Biological: Coxsackievirus A21
Completed Study Name: Safety and Clinical Activity of CAVATAK™ Alone or With Low Dose Mitomycin C in Non-muscle Invasive Bladder Cancer
Condition: Non-muscle Invasive Bladder Cancer
Date: 2014-12-07
Interventions:
  • Biological: CAVATAK CAVATAK is
Recruiting Study Name: Systemic Treatment Of Resistant Metastatic Disease Employing CVA21 and Pembrolizumab in Non-small Cell Lung Cancer and Bladder Cancer (STORM/ KEYNOTE-200)
Condition:
  • Non-small Cell Lung Cancer
  • Bladder Cancer

Date: 2014-01-19
Interventions: Biological: CVA21
Next >>>